1
|
Desroches-Castan A, Quélard D, Demeunynck M, Constant JF, Dong C, Keramidas M, Coll JL, Barette C, Lafanechère L, Feige JJ. A new chemical inhibitor of angiogenesis and tumorigenesis that targets the VEGF signaling pathway upstream of Ras. Oncotarget 2016; 6:5382-411. [PMID: 25742784 PMCID: PMC4467156 DOI: 10.18632/oncotarget.2979] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Accepted: 12/19/2014] [Indexed: 02/07/2023] Open
Abstract
The efficacy of anti-angiogenic therapies on cancer patients is limited by the emergence of drug resistance, urging the search for second-generation drugs. In this study, we screened an academic chemical library (DCM, University of Grenoble-Alpes) and identified a leader molecule, COB223, that inhibits endothelial cell migration and proliferation. It inhibits also Lewis lung carcinoma (LLC/2) cell proliferation whereas it does not affect fibroblast proliferation. The anti-angiogenic activity of COB223 was confirmed using several in vitro and in vivo assays. In a mouse LLC/2 tumor model, ip administration of doses as low as 4 mg/kg COB223 efficiently reduced the tumor growth rate. We observed that COB223 inhibits endothelial cell ERK1/2 phosphorylation induced by VEGF, FGF-2 or serum and that it acts downstream of PKC and upstream of Ras. This molecule represents a novel anti-angiogenic and anti-tumorigenic agent with an original mechanism of action that deserves further development as an anti-cancer drug.
Collapse
Affiliation(s)
- Agnès Desroches-Castan
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1036, Biology of Cancer and Infection, Grenoble, F-38054, France.,Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France
| | - Delphine Quélard
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1036, Biology of Cancer and Infection, Grenoble, F-38054, France.,Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France.,Janssen, Pharmaceutical Companies of Johnson and Johnson, Issy-les-Moulineaux, F-92130, France
| | - Martine Demeunynck
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Centre National de la Recherche Scientifique (CNRS), UMR 5063, Department of Molecular Pharmacochemistry, Grenoble, F-38041, France
| | - Jean-François Constant
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Centre National de la Recherche Scientifique (CNRS), UMR 5250, Department of Molecular Chemistry, Grenoble, F-38041, France
| | - Chongling Dong
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Centre National de la Recherche Scientifique (CNRS), UMR 5250, Department of Molecular Chemistry, Grenoble, F-38041, France
| | - Michelle Keramidas
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 823, Albert Bonniot Research Center, La Tronche, F-38700, France
| | - Jean-Luc Coll
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 823, Albert Bonniot Research Center, La Tronche, F-38700, France
| | - Caroline Barette
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1038, Large Scale Biology, Grenoble, F-38054, France
| | - Laurence Lafanechère
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 823, Albert Bonniot Research Center, La Tronche, F-38700, France
| | - Jean-Jacques Feige
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1036, Biology of Cancer and Infection, Grenoble, F-38054, France.,Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France
| |
Collapse
|
2
|
Liu Z, Lebrin F, Maring JA, van den Driesche S, van der Brink S, van Dinther M, Thorikay M, Martin S, Kobayashi K, Hawinkels LJAC, van Meeteren LA, Pardali E, Korving J, Letarte M, Arthur HM, Theuer C, Goumans MJ, Mummery C, ten Dijke P. ENDOGLIN is dispensable for vasculogenesis, but required for vascular endothelial growth factor-induced angiogenesis. PLoS One 2014; 9:e86273. [PMID: 24489709 PMCID: PMC3904881 DOI: 10.1371/journal.pone.0086273] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2013] [Accepted: 12/10/2013] [Indexed: 01/10/2023] Open
Abstract
ENDOGLIN (ENG) is a co-receptor for transforming growth factor-β (TGF-β) family members that is highly expressed in endothelial cells and has a critical function in the development of the vascular system. Mutations in Eng are associated with the vascular disease known as hereditary hemorrhagic telangiectasia type l. Using mouse embryonic stem cells we observed that angiogenic factors, including vascular endothelial growth factor (VEGF), induce vasculogenesis in embryoid bodies even when Eng deficient cells or cells depleted of Eng using shRNA are used. However, ENG is required for the stem cell-derived endothelial cells to organize effectively into tubular structures. Consistent with this finding, fetal metatarsals isolated from E17.5 Eng heterozygous mouse embryos showed reduced VEGF-induced vascular network formation. Moreover, shRNA-mediated depletion and pharmacological inhibition of ENG in human umbilical vein cells mitigated VEGF-induced angiogenesis. In summary, we demonstrate that ENG is required for efficient VEGF-induced angiogenesis.
Collapse
Affiliation(s)
- Zhen Liu
- Department of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - Franck Lebrin
- Hubrecht Institute, Utrecht, The Netherlands
- Center for Interdisciplinary Research in Biology (CIRB), CNRS UMR 7241/INSERM U1050, Collège de France, Paris, France
| | - Janita A. Maring
- Department of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | | | | | - Maarten van Dinther
- Department of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - Midory Thorikay
- Department of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - Sabrina Martin
- Center for Interdisciplinary Research in Biology (CIRB), CNRS UMR 7241/INSERM U1050, Collège de France, Paris, France
| | - Kazuki Kobayashi
- Department of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - Lukas J. A. C. Hawinkels
- Department of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - Laurens A. van Meeteren
- Department of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - Evangelia Pardali
- Department of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | | | - Michelle Letarte
- Molecular Structure and Function Program, The Hospital of Sick Children, Department of Immunology and Heart and Stroke Richard Lewar Center of Excellence, University of Toronto, Toronto, Ontario, Canada
| | - Helen M. Arthur
- Institute of Genetic Medicine, Newcastle University, International Centre for Life, Newcastle upon Tyne, United Kingdom
| | - Charles Theuer
- Tracon Pharmaceuticals, San Diego, California, United States of America
| | - Marie-José Goumans
- Department of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands
- * E-mail: (MJG); (CM); (PtD)
| | - Christine Mummery
- Hubrecht Institute, Utrecht, The Netherlands
- Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, The Netherlands
- * E-mail: (MJG); (CM); (PtD)
| | - Peter ten Dijke
- Department of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands
- * E-mail: (MJG); (CM); (PtD)
| |
Collapse
|